financial highlights

Operating EBITDA grew by 44 per cent to Rs 202 crore

India formulation sales for Q2 FY2023 were Rs 15,841 mn, up 6.2 per cent as compared to Rs 14,920 mn in Q1 FY2023

Revenue from operation grew by 11 per cent to Rs 3,202 crore versus Rs 2,889 crore in H1FY22

Pharma revenue up 50 per cent with expanding contribution from Latin America

EBITDA at Rs 1,514 million, with 32.9 per cent EBITDA margin; PAT stood at Rs 1,194 million, with 25.9 per cent PAT margin

Sales of health products grew by 42 per cent on back of a strong momentum gained from new product introductions and territorial…

Total income in Q1FY23 at Rs 129.97 crore, up 24.4 per cent from Rs 104.4 crore in Q4FY22

Profit After Tax (PAT) up 32 per cent YoY

The company had posted a net profit of Rs 321 crores for the corresponding period of the previous fiscal

YoY, EBITDA at Rs 193 crores, EBITDA margin at 19 per cent; PAT at Rs 111 crores